Lilly strikes again, buying Calytrix in $1.5bn deal
Eli Lilly has added yet another name to its list of M&A deals this year after agreeing to buy blood disorder specialist Calytrix Bio for up to $1.5bn.
Gazyva is first FDA-cleared drug for rare disease pMN
Patients in the US with primary membranous nephropathy have a first approved drug, after the FDA cleared Roche's Gazyva for the rare kidney disorder.
AZ's Alexion extends gMG options with two Klygefa approvals
AstraZeneca's Alexion unit has won approval in the US and EU for Klygefa, billed as a future blockbuster, for generalised myasthenia gravis (gMG).
China overtakes Europe in healthcare investing sentiment
China has overtaken Europe as the preferred location for healthcare investing, according to Jefferies' Healthcare Temperature Check report.
FDA won't approve Summit, Akeso's ivonescimab
The FDA has said it cannot approve Summit /Akeso's ivonescimab, delaying a drug that could usher in a new era of dual-acting cancer immunotherapies.
Partner Content
The PM Awards aren’t just for agencies. They’re for the peop...
For decades, the PM Awards have been a fixture in the pharma and healthcare communications calendar
PMi Awards 2026: innovation, connection and a changing indus...
One of the things I enjoyed most about this year’s PM Society PMi Awards was the sheer breadth of the community in the room.
LEAP HR: Life Sciences Europe
Europe’s Only Industry-Specific Meeting Advancing HR Excellence in Life Sciences
Rational Based Drug Design Summit Europe
Driving Safer, Faster & More Efficient Discovery Across Europe
Evolution Summit 2027 to Convene Senior Clinical Development...
Westlake Village, CA: Marcus Evans today announced the Evolution Summit 2027, an invitation-only gathering of senior clinical trial executives
